A combination of serological tests to quantify both the interferon‐gamma release by SARS‐CoV‐2‐specific T cells, stimulated by SARS‐CoV‐2 specific antigens and the presence of anti‐S1/RBD IgG antibodies will enable differentiated investigation of the immune response in the progression of infection and vaccination. The gene discussed is PSMD1; the disease is infection.